Evidence map›Paper›PMID 15994763›Full record

ArticleJournal of virology2005

Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.

Kevin Whitby, Theodore C Pierson, Brian Geiss, Kelly Lane, Michael Engle, Yi Zhou, Robert W Doms, Michael S Diamond

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02569827 (A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore), which is not on this map. Cited by 124 papers.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02569827 phase1 / phase2withdrawnnot on this mapstarted 2018, after this paper: background citation

A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore

TypeinterventionalSponsorSingapore General HospitalRan2018 to 2019Enrolled0ConditionsDengue FeverArmsCelgosivir, Modipafant 50mg, Placebo, Modipafant 100mg
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 289 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Current pharmaceutical biotechnology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Molecules (Basel, Switzerland) · 2024
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kevin WhitbyDepartment of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St. Louis, MO 63110, USA.
Theodore C Pierson
Brian Geiss
Kelly Lane
Michael Engle
Yi Zhou
Robert W Doms
Michael S Diamond
University of Pennsylvania · USApath (United States) · USWashington University in St. Louis · US

Funding

Vaccine strategy for broad spectrum protection agains non-typhoidal salmonellU54AI057168 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CROSS, ALAN S. · 2003 to 2013
$91.5M
NIAID NIH HHS U01 AI538870NIAID NIH HHS U54 AI057168NIAID NIH HHS U54 AI57168
6 · The paper itself

Abstract

Previous studies have suggested that alpha-glucosidase inhibitors such as castanospermine and deoxynojirimycin inhibit dengue virus type 1 infection by disrupting the folding of the structural proteins prM and E, a step crucial to viral secretion. We extend these studies by evaluating the inhibitory activity of castanospermine against a panel of clinically important flaviviruses including all four serotypes of dengue virus, yellow fever virus, and West Nile virus. Using in vitro assays we demonstrated that infections by all serotypes of dengue virus were inhibited by castanospermine. In contrast, yellow fever virus and West Nile virus were partially and almost completely resistant to the effects of the drug, respectively. Castanospermine inhibited dengue virus infection at the level of secretion and infectivity of viral particles. Importantly, castanospermine prevented mortality in a mouse model of dengue virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at promoting survival (P < or = 0.0001). Correspondingly, castanospermine had no adverse or protective effect on West Nile virus mortality in an analogous mouse model. Overall, our data suggest that castanospermine has a strong antiviral effect on dengue virus infection and warrants further development as a possible treatment in humans.

Indexed as

AnimalsAntiviral AgentsDengueDengue VirusIndolizidinesIndolizinesMiceMice, Inbred C57BLRNA, ViralVirionWest Nile FeverWest Nile virusYellow fever virusAntiviral AgentscastanospermineIndolizidinesIndolizinesRNA, Viral

Identifiers

PMID15994763
PMCPMC1168722
OpenAlexW2159415883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.